Events

Regenerative medicine company Orthocell (ASX:OCC) has announced the publication of positive pre-clinical and clinical results for the use of its CelGro in enhancing repair of critical bone defects in the 'Tissue Engineering' Journal.

Australian company CLINUVEL (ASX:CUV) has announced it has dosed the first patient in its SCENESSE DNA Repair Program.

Experts are noting that healthcare is faring well on the investment ‘front’, recession-proof even, but the full scale of the impact of COVID-19 is yet to be realised, especially for life sciences companies requiring substantial investment from public and private sources to commercialise medical research.  

Australian respiratory company Rhinomed (ASX:RNO) says it is advanced in developing a new high-yielding nasal swab that can collect samples from the nose to test for the presence of upper respiratory tract diseases, including influenza and coronavirus strains.

CSIRO says a new report has revealed the opportunities for industries to leverage science and technology and help restore economic growth and resilience.

Melbourne-based clinical-stage biopharmaceutical company Dimerix (ASX:DSB) has updated on clinical trials of its drug candidate DMX-200 for kidney diseases.

Melbourne-based health tech innovation and commercialisation company Planet Innovation has partnered with US-based Levitas Bio to launch the world’s first label-free cell separation platform, the LeviCell.

Soft-tissue regeneration company Aroa Biosurgery (ASX:ARX) has provided an update it says highlights the recovery in its sales that were impacted by the COVID-19 pandemic in the June quarter. 

Starpharma (ASX:SPL) has halted the laboratory testing of its antiviral SPL7013 against COVID-19 after confirmation it is more than 99.9 per cent effective against the virus.

The Australian Commission on Safety and Quality in Health Care has announced the opening of the pilot of the National Clinical Trials Governance Framework that will be conducted through March 2021.

Adelaide-based CAR-T biotherapeutics company Carina Biotech has announced a co-development agreement with immuno-oncology company Glytherix it says could result in a promising new therapy that is effective in killing a range of cancers. 

Guiding principles on optimising digital technology for executing clinical trial research agreements using eSignatures has been released in a new position statement - Electronic signatures and clinical trial research agreement execution in Australia.